How big? Well at the recent JP Morgan conference, a Hospira spokesman put the figure at a potential $250 B. For that reason alone, Hospira thinks biosimilars will make it very successfully in the USA despite no products coming through the FDA as yet. Hospira syas it expects to submit its first application to FDA within a year and say they have a biosimilar pipeline in R&D worth more than $40 B in local currency. Big talk and big aspirations.
Hospira does have three marketed biosimilars in Europe, including the world's first monoclonal antibody, Inflectra. Hospira says its biosimilar Filigrastim has taken 60-70% of the market share of Amgen's branded Neupogen in Europe and they want to do the same in the USA. Hospira says a biosimilar behaves much differently than a small molecule generic. It has a much slower ramp up period but then has a much longer share of market. Instead, you get a nice profitable build of business. See Biopharma-Reporter.
Posted by Bruce Lehr Jan 22nd 2014.